Candel Therapeutics (CADL) Invested Capital (2020 - 2025)

Candel Therapeutics' Invested Capital history runs 6 years deep, the most recent figure standing at $51.9 million for Q4 2025.

• In Q4 2025, Invested Capital fell 31.88% year-over-year to $51.9 million; the TTM figure through Dec 2025 stood at $51.9 million (down 31.88% YoY), while the FY2025 annual figure was $51.9 million, down 31.88% from the prior year.
• Invested Capital came in at $51.9 million for Q4 2025 at Candel Therapeutics, down from $84.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $96.9 million in Q2 2025 to a low of -$42.7 million in Q2 2021.
• A 5-year average of $44.6 million and a median of $57.7 million in 2021 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital sank 245.63% in 2021 and surged 59556.44% in 2025, its largest moves.
• Candel Therapeutics' Invested Capital stood at $64.7 million in 2021, then climbed by 4.66% to $67.7 million in 2022, then plunged by 68.05% to $21.6 million in 2023, then surged by 252.26% to $76.2 million in 2024, then tumbled by 31.88% to $51.9 million in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $51.9 million, $84.3 million, and $96.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison